Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with...
The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis (RVCC) who received monthly single-day...
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Submission has been granted priority review and given a target regulatory decision date of November 30, 2022.If approved for this...
MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Progyny Outcomes Consistently Exceed National Benchmarks Across Key Clinical Measures of Fertility Success Progyny's Superior Clinical Outcomes The outcomes of...
-- European Commission decision anticipated in fourth quarter of 2022 -- BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals,...
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand...
CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA)...
Data show that 71% of 24 patients with recurrent vulvovaginal candidiasis (RVVC) who failed to respond to a three-day regimen...
The New Wellness Platform is Redefining Accessible Mental Healthcare, Putting the Benefits of Therapy in Members' Hands With the Launch...
Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the...
Genetic testing is increasing in popularity for many different areas of healthcare, and it’s well-funded and expected to keep advancing...